Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
Anika (NASDAQ: ANIK) will release its fourth quarter and year-end 2025 financial results before market open on Thursday, February 26, 2026.
Rhea-AI Summary
Anika (NASDAQ: ANIK) will release its fourth quarter and year-end 2025 financial results before market open on Thursday, February 26, 2026.
A conference call to discuss results and business highlights will follow at 8:30 a.m. ET. Investors can join via dial-in, a live audio webcast, and an archived presentation on Anika's investor website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ANIK
On Feb 13, the first trading day after this news, ANIK closed 1.49% above the previous close.
Data tracked by StockTitan Argus for the Feb 13 session.
Key Figures
- Earnings release date
- February 26, 2026
- Q4 and year-end 2025 financial results release before market open
- Conference call time
- 8:30 a.m. ET
- Scheduled earnings conference call on February 26, 2026
- Conference ID
- 89327
- ID required to join the Q4 and year-end 2025 earnings call
- Domestic dial-in
- 1-800-717-1738
- Toll-free U.S. access number for the earnings conference call
- International dial-in
- 1-646-307-1865
- International access number for the earnings conference call
Previous Earnings Reports
-
Reported Q3 2025 revenue decline with mixed channel performance and key milestones.
-
Announced Q3 2025 earnings release date and conference call details.
-
Q2 2025 revenue decline, adjusted outlook and continued losses from continuing operations.
-
Set Q2 2025 earnings release date and outlined access details for the call.
-
Q1 2025 total revenue decline, OEM weakness and updated 2025 guidance range.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2025 financial results before the opening of the market on Thursday, February 26, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 89327. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.anika.com. The call will be archived and accessible on the same website shortly after its conclusion.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.